Loading...
Loading...
Browse all stories on DeepNewz
VisitFirst country to approve Yamanaka factor-based treatment by end of 2026?
United States • 25%
China • 25%
European Union • 25%
Other • 25%
Official government or regulatory announcements
OpenAI's GPT-4b Micro Model Aids Retro Biosciences in Enhancing Yamanaka Factors for Longevity
Jan 17, 2025, 07:09 PM
OpenAI has developed a new AI model named GPT-4b micro in collaboration with Retro Biosciences, a longevity startup, to enhance the process of cell reprogramming. The model focuses on re-engineering Yamanaka factors, a set of proteins that can transform regular cells into stem cells. This collaboration, initiated a year ago, aims to increase the efficiency of cell reprogramming, which is currently a slow and inefficient process. The GPT-4b micro model has been trained to suggest modifications to the Yamanaka factors, resulting in versions that are reported to be more than 50 times as effective in preliminary tests. The project represents OpenAI's foray into scientific discovery, specifically targeting biological data and protein engineering. Retro Biosciences, backed by a $180 million investment from Sam Altman, OpenAI's CEO, is working towards extending the human lifespan by 10 years. The collaboration between OpenAI and Retro Biosciences is part of a broader effort to accelerate scientific discovery and innovation in the field of longevity science.
View original story
EU • 25%
USA • 25%
Other • 25%
China • 25%
Other • 25%
Australia • 25%
Canada • 25%
United Kingdom • 25%
Moderate Improvement • 25%
No Improvement • 25%
Harmful Effects • 25%
Significant Improvement • 25%
United States • 25%
European Union • 25%
China • 25%
Other • 25%
Cancer Therapy • 25%
Other • 25%
Anti-Aging Treatments • 25%
Regenerative Medicine • 25%
European Union • 25%
United States • 25%
China • 25%
Other • 25%
Other • 25%
United States • 25%
European Union • 25%
China • 25%
Canada • 25%
Other • 25%
Australia • 25%
United Kingdom • 25%
Japan • 25%
Other • 25%
United States • 25%
European Union • 25%
Other • 25%
Canada • 25%
Australia • 25%
United Kingdom • 25%
Other • 25%
European Union • 25%
China • 25%
United States • 25%
Germany • 25%
Other • 25%
United States • 25%
United Kingdom • 25%
Yes • 50%
No • 50%
No • 50%
Yes • 50%
More than $300 million • 25%
Less than $100 million • 25%
$100 million to $200 million • 25%
$200 million to $300 million • 25%